Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction

Heart Fail Clin. 2024 Jan;20(1):39-50. doi: 10.1016/j.hfc.2023.05.008. Epub 2023 Jun 26.

Abstract

A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality of life, decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), and improving functional class. BAT was approved by the FDA for improvement of symptoms of heart failure for patients who remain symptomatic despite treatment with guideline-directed management, are New York Heart Association Class III or Class II (with a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, an NT-proBNP < 1600 pg/mL and excluding patients indicated for cardiac resynchronization therapy.

Keywords: Autonomic nervous system; Baroreflex; Exercise capacity; Functional status; Heart failure; Quality of life.

Publication types

  • Review

MeSH terms

  • Baroreflex / physiology
  • Heart Failure*
  • Humans
  • Natriuretic Peptide, Brain
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Stroke Volume / physiology
  • Ventricular Dysfunction, Left*
  • Ventricular Function, Left

Substances

  • Natriuretic Peptide, Brain